This episode's conversation focuses on the innovative work of Dr. Catriona Jamieson, Director of the Sanford Stem Cell Institute at UC San Diego, and the Axiom-4 (Ax-4) launch.  This space research mission includes the Institute's testing of the efficacy of "rebecsnib" on tumor organoids derived from cancer stem cells of consenting patients with secondary acute myeloid leukemia, ovarian cancer, metastatic breast cancer and glioblastoma multiforme. The drug holds potential to fight 23 types of cancer — any that involve ADAR1 in their development and progression. The hope is that the investigational new drug prevents the miniature tumors from growing, as it did on Axiom Space's previous Ax-3 mission, with cell line-derived triple negative breast cancer tumor organoids.  Hosted by Bobby Gordon This episode was recorded on June 6, 2025, and information presented is accurate as of this date.

Ver todos los episodios